The objective of this study is to investigate the relationship between soluble components of the
interleukin 6 (IL-6) system mediating and modifying
IL-6 trans-signaling and the RANKL-RANK-
osteoprotegerin system in postmenopausal women with
rheumatoid arthritis (RA). The following parameters were investigated in 126 postmenopausal women with RA:
IL-6, soluble IL-6-receptor (sIL-6R),
soluble glycoprotein 130 (
sgp130), sRANKL,
osteoprotegerin (OPG),
osteocalcin, erythrocyte sedimentation rate and
C-reactive protein in sera, pyridinolin and desoxypyridinolin crosslinks in the morning urine. Bone mineral density (BMD) was measured by dual X-ray absorptiometry at the lumbar spine (BMD-LS) and at the femoral neck (BMD-FN). Predictors of RANKL/OPG ratio and BMD were evaluated by multiple linear regression analysis. The following determinants of the RANKL/OPG ratio were identified: sIL-6R/
sgp130 ratio and daily
glucocorticoid (GC) dose as positive determinants in the whole group (R (2) = 0.56; P = 0.001), sIL-6R/
sgp130 ratio as the exclusive positive determinant in patients with GC
therapy (R (2) = 0.48; P = 0.001) and
sgp130 as negative determinant in patients without GC (R (2) = 0.42; P = 0.031).
Sgp130 was highly significantly positively correlated with OPG in the whole group (P < 0.001) as well as in patients with (n = 70; P < 0.05) and without GC
therapy (n = 56; P < 0.01). sIL-6R was the main negative predictor of BMD-LS (R (2) = 0.41; P = 0.019). High sIL-6R/
sgp130 ratio and/or low
sgp130 are associated with a high sRANKL/OPG ratio in sera of postmenopausal women with RA indicating the critical significance of
IL-6 trans-signaling for an increase in the RANKL/OPG ratio and of
bone resorption. Inhibition of
IL-6 trans-signaling may be an effective bone-protecting principle in postmenopausal women with RA.